This white paper presents a clinical evaluation of MV-Flow™, an advanced Doppler ultrasound technology that enhances the assessment of renal masses by detecting microvascular blood flow not visible with conventional color or power Doppler techniques. MV-Flow™ improves visualization of low-velocity blood flow, offering greater diagnostic sensitivity and tissue differentiation in both solid and cystic kidney lesions.
Through three clinical case studies, the paper demonstrates MV-Flow™’s ability to reveal subtle vascularity within renal masses. In each case—including clear cell renal cell carcinoma and a mixed epithelial stromal tumor—conventional Doppler imaging failed to capture significant blood flow, while MV-Flow™ successfully visualized internal vascular signals. The findings were further confirmed by contrast-enhanced ultrasound (CEUS), showing that MV-Flow™ can serve as a reliable, contrast-free alternative for lesion characterization.
MV-Flow™ is especially valuable in kidney ultrasound imaging when evaluating indeterminate lesions or in settings where contrast use is not feasible. It improves diagnostic confidence by supporting more accurate differentiation between benign and malignant features based on vascular flow patterns.
The evaluation was conducted using the Samsung Medison RS85 system. MV-Flow™ is also available on several other Samsung ultrasound platforms, including HERA W10, HERA I10, HERA W9, RS85, RS80 EVO, V8, V7, and HS60.
These systems provide healthcare professionals with access to high-sensitivity Doppler imaging tools that improve diagnostic outcomes in real-world clinical environments, particularly in renal mass evaluation.
